Physician profile
Marion E Hord
NPI 1235194481
$1,789.71
in general payments reported to CMS, 2019-2025
26 companies · $75.43 in 2025
The $75.43 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $155 · 2021: $344 · 2022: $247 · 2023: $332 · 2024: $126 · 2025: $75.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $276.86 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.92 | 2019-2023 | Xifaxan, Trulance |
| Abbvie INC. | $153.15 | 2021-2025 | |
| Pfizer INC. | $132.59 | 2019-2024 | |
| Novo Nordisk INC | $126.82 | 2019-2025 | Rybelsus, Ozempic, Saxenda |
| Takeda Pharmaceuticals U.S.A., INC. | $115.68 | 2019-2021 | |
| Corium, LLC | $78.09 | 2023 | Azstarys |
| Merck Sharp & Dohme LLC | $73.94 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $60.03 | 2019-2025 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $53.93 | 2019-2022 | |
| Allergan, INC. | $51.05 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $49.09 | 2019 | |
| Mylan Specialty L.P. | $39.22 | 2019-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $37.58 | 2019-2022 | |
| Lilly USA, LLC | $37.33 | 2019-2023 | Mounjaro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $35.30 | 2020 | |
| Dexcom, INC. | $35.19 | 2024 | Dexcom G6 Transmitter |
| Shire North American Group INC | $34.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $31.52 | 2019 | |
| Teleflex LLC | $28.38 | 2024 | Urolift |
| Kowa Pharmaceuticals America, INC. | $24.13 | 2022 | |
| Esperion Therapeutics, INC. | $24.10 | 2020-2021 | |
| Radius Health, INC. | $22.29 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $19.14 | 2022 | |
| Sunovion Pharmaceuticals INC. | $13.79 | 2021 | |
| Ironshore Pharmaceuticals INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marion Hord listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.